Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.12 USD | +0.06% | -2.89% | -22.78% |
Financials (USD)
Sales 2024 * | 694M | Sales 2025 * | 764M | Capitalization | 1.21B |
---|---|---|---|---|---|
Net income 2024 * | 60M | Net income 2025 * | 91M | EV / Sales 2024 * | 1.87 x |
Net Debt 2024 * | 83.94M | Net cash position 2025 * | 119M | EV / Sales 2025 * | 1.43 x |
P/E ratio 2024 * |
21.3
x | P/E ratio 2025 * |
13.4
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.78% |
Latest transcript on Pacira BioSciences, Inc.
1 day | -2.50% | ||
1 week | -4.61% | ||
Current month | -10.68% | ||
1 month | -10.89% | ||
3 months | -17.74% | ||
6 months | -11.22% | ||
Current year | -22.64% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Director of Finance/CFO | 63 | 11-10-31 | |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 27 M€ | -7.00% | - | |
0.18% | 45 M€ | -2.89% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 26.1 | 0.00% | 102 473 |
24-04-18 | 26.1 | -2.50% | 622,151 |
24-04-17 | 26.77 | -0.37% | 415,509 |
24-04-16 | 26.87 | +1.28% | 721,374 |
24-04-15 | 26.53 | -1.12% | 604,436 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.64% | 1.21B | |
+27.97% | 672B | |
+23.62% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+1.91% | 211B | |
-0.52% | 203B | |
-10.31% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- PCRX Stock